Phase 2 Study of CAN008 in Subjects With GBM

This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 study whose objectives are to evaluate the clinical efficacy and safety of CAN008 plus TMZ during and after radiation thera...

Lead sponsor: CANbridge Life Sciences Ltd.•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Qionghui Qiu

CONTACT

+86 21 52996609 [email protected]

Fangmin Huang

CONTACT

[email protected]

Trial snapshot

StatusUNKNOWN

PhasePHASE2

Enrollment117

Start dateOct 2021

Last updatedJul 12, 2022

Condition

Newly-diagnosed Glioblastoma

Locations shown

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 12, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions